Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer
- PMID: 22995648
- DOI: 10.1016/j.breast.2012.08.002
Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer
Abstract
Background: We examined mRNA expression for MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 in human breast cancer tissues, and the association between their expression and clinicopathological variables.
Patients and methods: Breast tissue samples from 120 patients with breast cancer were available for this study. To determine mRNA expression for MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2, semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was carried out on tumor and normal tissues, respectively.
Results: Mean MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 mRNA expression in the breast cancer was significantly higher than in the normal tissue. In terms of tumor size and lymph node metastasis of breast cancer, the differences in MMP-2, MMP-7, MMP-9, and MT1-MMP mRNA expression levels were significant.
Conclusion: The association between the increased expression of MMP-2, MMP-7, MMP-9, and MTI-MMP and clinicopathological parameters reflects a role in predicting the aggressive behavior of breast cancer.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.Int J Oncol. 2000 Oct;17(4):673-81. Int J Oncol. 2000. PMID: 10995877
-
[Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].Ai Zheng. 2004 Oct;23(10):1194-8. Ai Zheng. 2004. PMID: 15473934 Chinese.
-
[Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].Ai Zheng. 2003 Sep;22(9):968-73. Ai Zheng. 2003. PMID: 12969531 Chinese.
-
Gene Polymorphisms and Circulating Levels of MMP-2 and MMP-9: A Review of Their Role in Breast Cancer Risk.Anticancer Res. 2020 Jul;40(7):3619-3631. doi: 10.21873/anticanres.14351. Anticancer Res. 2020. PMID: 32620601 Review.
-
Predicting affinity- and specificity-enhancing mutations at protein-protein interfaces.Biochem Soc Trans. 2013 Oct;41(5):1166-9. doi: 10.1042/BST20130121. Biochem Soc Trans. 2013. PMID: 24059503 Review.
Cited by
-
Silencing of KIF3B Suppresses Breast Cancer Progression by Regulating EMT and Wnt/β-Catenin Signaling.Front Oncol. 2021 Jan 19;10:597464. doi: 10.3389/fonc.2020.597464. eCollection 2020. Front Oncol. 2021. PMID: 33542902 Free PMC article.
-
Impacts of Matrix Metalloproteinase-2 Promoter Genotypes on Breast Cancer Risk.Cancer Genomics Proteomics. 2024 Sep-Oct;21(5):502-510. doi: 10.21873/cgp.20467. Cancer Genomics Proteomics. 2024. PMID: 39191502 Free PMC article.
-
The expression of matrix metalloproteinase 2, 9 and 11 in Ethiopian breast cancer patients.BMC Res Notes. 2023 Oct 5;16(1):253. doi: 10.1186/s13104-023-06518-5. BMC Res Notes. 2023. PMID: 37798646 Free PMC article.
-
Plasma matrix metalloproteinase 1, 3, and 7 levels and breast cancer risk in the Nurses' Health study.Cancer Causes Control. 2014 Dec;25(12):1717-23. doi: 10.1007/s10552-014-0462-7. Epub 2014 Sep 16. Cancer Causes Control. 2014. PMID: 25225035 Free PMC article.
-
Plasma Levels of Metalloproteinase 3 (MMP-3) and Metalloproteinase 7 (MMP-7) as New Candidates for Tumor Biomarkers in Diagnostic of Breast Cancer Patients.J Clin Med. 2023 Mar 30;12(7):2618. doi: 10.3390/jcm12072618. J Clin Med. 2023. PMID: 37048701 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous